CMRX - Chimerix, Inc.
3.43 0.00 (0.00%)
After hours: 5:02PM EST
| Previous Close | 3.3800 |
| Open | 3.4500 |
| Bid | 2.85 x 800 |
| Ask | 6.75 x 800 |
| Day's Range | 3.3700 - 3.5110 |
| 52 Week Range | 3.1100 - 5.9400 |
| Volume | 251,720 |
| Avg. Volume | 218,458 |
| Market Cap | 173.984M |
| Beta (3Y Monthly) | 1.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.54 |
| Earnings Date | Feb 27, 2019 - Mar 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
- GlobeNewswire•9 days ago
New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Associated Press•last month
Chimerix: 3Q Earnings Snapshot
The Durham, North Carolina-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•last month
Chimerix Announces Third Quarter 2018 Financial Results
- Conference Call at 8:30 a.m. ET Today - DURHAM, N.C., Nov. 08, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address.
- GlobeNewswire•last month
Chimerix to Present at the Stifel 2018 Healthcare Conference
DURHAM, N.C., Nov. 07, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today.
- American City Business Journals•last month
The most valuable public companies in the Triangle (Slideshow)
The number of public companies based in the Triangle has shrunk in recent years as acquisitions have meant a change in headquarters location, or even taking the company private.
- GlobeNewswire•last month
Chimerix to Announce Third Quarter 2018 Financial Results on November 8, 2018
DURHAM, N.C., Nov. 01, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today announced.
- GlobeNewswire•last month
Chimerix Presents Preclinical Data Demonstrating Antiviral Activity of Brincidofovir Against Polyomavirus at Kidney Week 2018
Chimerix (CMRX) today announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir (BCV) against polyomavirus. Polyomaviruses are a family of small DNA viruses that persistently infect their hosts for life.
- GlobeNewswire•2 months ago
Report: Developing Opportunities within Univar, Aqua America, Chimerix, Superior Energy Services, TechTarget, and ZIOPHARM Oncology — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Chimerix to Host Annual Investor Update on October 17, 2018
DURHAM, N.C., Oct. 11, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host.
- Simply Wall St.•2 months ago
How Should You Think About Chimerix Inc’s (NASDAQ:CMRX) Risks?
If you’re interested in Chimerix Inc (NASDAQ:CMRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
- GlobeNewswire•2 months ago
Chimerix Presents Results from Multiple Ascending Dose Study of IV Brincidofovir at IDWeek
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from the company’s Phase 1 study evaluating the safety and pharmacokinetics (PK) of multiple ascending doses (MAD) of intravenous (IV) brincidofovir (BCV) in healthy subjects. “This study shows that four weekly or twice-weekly doses of the IV formulation of brincidofovir are generally well tolerated, and the 10 mg dose provides similar blood levels as the oral 100 mg dose with no reported gastrointestinal side effects,” said Garrett Nichols, MD, MS, Chief Medical Officer of Chimerix.
- GlobeNewswire•2 months ago
Landmark AdVance Study Shows Adenovirus Burden Correlates with Mortality in Pediatric Allogeneic Hematopoietic Cell Transplant Recipients
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced the full analysis of adenovirus (AdV) viral load dynamics and all-cause mortality in pediatric patients. Prior to the AdVance study, the epidemiology of AdV after allo-HCT has been generally understood via single-center studies, with little data on the correlation between AdV viral load and risk of mortality. “AdVance represents a significant step forward in our understanding of the impact of adenovirus on allo-HCT recipients.
- GlobeNewswire•3 months ago
Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference
DURHAM, N.C., Sept. 26, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle.
- Zacks•4 months ago
Chimerix (CMRX) Reports Q2 Loss, Tops Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 11.36% and 27.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•4 months ago
Chimerix: 2Q Earnings Snapshot
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 39 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- ACCESSWIRE•4 months ago
Chimerix, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30 AM Eastern Time. To ...
Market Realist•5 months agoContraVir Stock Rose on Clinical Trial Progress Report
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
